SEC Form 4 · accession 0001209191-18-034891
Insight Molecular Diagnostics Inc. · IMDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mitchell S Levine
Officer — Chief Financial Officer
Period of report
May 23, 2018
Accepted (ET)
Jun 1, 2018 · 9:26 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001642380
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF1 | $2.35 | May 23, 2018 | A | 50,000 | A | — | May 22, 2028 | Common Stock | 50,000 | 50,000 | D |
| Option to Purchase Common StockF2 | $2.35 | May 23, 2018 | A | 125,000 | A | — | May 22, 2028 | Common Stock | 125,000 | 125,000 | D |
| Option to Purchase Common StockF3 | $5.90 | holding | — | — | — | — | Nov 14, 2027 | Common Stock | 200,000 | 200,000 | D |
Explanation of responses
- F1One quarter of the options shall vest on the one-year anniversary of the grant date and the balance shall vest thereafter in 36 equal monthly installments.
- F2These options vest as to one-third of the shares on each of the completion of the clinical utility study for OncoCyte's DetermaVu product candidate, the filing of the Medicare dossier for the Medicare local coverage determination, and obtaining a Medicare local coverage determination for OncoCyte's DetermaVu product candidate.
- F3One quarter of the options shall vest on November 14, 2018, subject to the completion of 12 months of continuous employment from the date of grant, and the balance shall vest in 36 monthly installments upon the completion of each month of continuous employment from the first anniversary of the date of grant.